Effects of Monoclonal Antibodies on B Cell Leukaemia
Author Information
Author(s): Loisel Séverine, André Pierre-Alain, Golay Josee, Buchegger Franz, Kadouche Jean, Cérutti Martine, Bologna Luca, Kosinski Marek, Viertl David, Delaloye Angelika Bischof, Berthou Christian, Mach Jean-Pierre, Boumsell Laurence
Primary Institution: Université Européenne de Bretagne
Hypothesis
Can the combined use of monoclonal antibodies enhance the therapeutic potential against B cell leukaemia?
Conclusion
The combined use of anti-HLA-DR and anti-CD5 monoclonal antibodies significantly enhances their therapeutic potential against B cell leukaemia.
Supporting Evidence
- The three monoclonal antibodies showed high and specific binding capacity to various human leukaemia target cells.
- Only the anti-HLA-DR mAb induced complement mediated lysis.
- Combined injection of anti-CD5 with anti-HLA-DR led to longer mouse survival.
Takeaway
This study looked at how different antibodies can help fight a type of blood cancer. Using two antibodies together worked better than using just one.
Methodology
The study evaluated the binding capacity, anti-proliferative, and apoptotic effects of three monoclonal antibodies in vitro and their antitumour efficacy in vivo using SCID mice models.
Limitations
The study primarily used mouse models, which may not fully replicate human responses.
Participant Demographics
The study involved human B-CLL cells from patients and SCID mice for in vivo experiments.
Statistical Information
P-Value
p<0.005
Statistical Significance
p<0.005
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website